Sleep Apnea: Obstructive, Central, and Complex

Sleep apnea is a sleep-related breathing disorder characterized by repeated interruptions to airflow during sleep, each lasting at least 10 seconds by standard diagnostic criteria (American Academy of Sleep Medicine, ICSD-3). Three distinct subtypes — obstructive, central, and complex — differ in their underlying physiology, causal drivers, and treatment response. The disorder carries documented associations with cardiovascular, metabolic, and cognitive outcomes, and it intersects with federal safety regulations governing commercial transportation and aviation. This page provides a comprehensive reference covering definitions, mechanics, classification boundaries, and common misconceptions for all three subtypes.

Definition and Scope

Sleep apnea is defined in the International Classification of Sleep Disorders, Third Edition (ICSD-3), published by the American Academy of Sleep Medicine (AASM), as a disorder of repetitive upper airway obstruction or respiratory control failure during sleep. The defining metric is the Apnea-Hypopnea Index (AHI): the number of apneas and hypopneas per hour of sleep. An AHI of 5–14 events per hour classifies as mild, 15–29 as moderate, and ≥30 as severe (AASM, ICSD-3).

Prevalence estimates from the Wisconsin Sleep Cohort and the Sleep Heart Health Study — both large-scale epidemiological studies funded through the National Heart, Lung, and Blood Institute (NHLBI) — indicate that moderate-to-severe sleep apnea (AHI ≥15) affects approximately 10% of adult men and 3% of adult women in the United States, though many cases remain undiagnosed.

The disorder's public health significance is reinforced by regulatory frameworks. The Federal Motor Carrier Safety Administration (FMCSA) and the Federal Aviation Administration (FAA) both maintain guidance on sleep apnea screening for commercial drivers and pilots, respectively, given documented impairment of alertness and reaction time. The broader regulatory context for sleep encompasses these occupational safety requirements alongside clinical diagnostic standards.

Core Mechanics or Structure

Obstructive Sleep Apnea (OSA)
In OSA, the upper airway collapses partially or completely during sleep despite continued respiratory effort from the diaphragm and intercostal muscles. The anatomical site most frequently implicated is the retropalatal or retroglossal segment of the pharynx. During sleep, muscle tone in the genioglossal and palatopharyngeal muscles decreases; when this relaxation exceeds a threshold, the airway narrows or closes. Each obstruction terminates in an arousal or microarousal — a partial awakening that restores muscle tone and reopens the airway, typically without the sleeper's conscious awareness.

Central Sleep Apnea (CSA)
CSA involves a failure of respiratory drive rather than anatomical obstruction. The brainstem's pre-Bötzinger complex and associated respiratory control centers fail to transmit timely signals to the respiratory muscles. The chest wall does not move; no effort is made. CSA frequently presents as a Cheyne-Stokes breathing pattern — a cyclical crescendo-decrescendo tidal volume pattern — particularly in patients with congestive heart failure or stroke. The NHLBI classifies CSA subtypes by etiology, including idiopathic CSA, CSA due to Cheyne-Stokes breathing, high-altitude periodic breathing, and opioid-induced CSA.

Complex Sleep Apnea (CompSAS / Treatment-Emergent CSA)
Complex sleep apnea, also termed treatment-emergent central sleep apnea, describes a condition in which OSA is diagnosed polysomnographically, but upon initiation of continuous positive airway pressure (CPAP) therapy, a significant central apnea component emerges or persists. The AASM recognizes this as a distinct entity in the ICSD-3. The underlying mechanism is debated, but involves ventilatory instability driven by a high loop gain — a measure of the sensitivity of the respiratory control system — that becomes unmasked when CPAP eliminates obstructive events.

Causal Relationships or Drivers

OSA risk factors are anatomical, physiological, and behavioral. A body mass index ≥30 kg/m² is consistently associated with elevated OSA risk across the Sleep Heart Health Study dataset. Craniofacial features — retrognathia, a high and narrow hard palate, enlarged tonsils and adenoids — reduce upper airway caliber independently of weight. Male sex, post-menopausal hormonal status, and advancing age all alter upper airway muscle tone and pharyngeal fat deposition.

CSA drivers are predominantly neurological and cardiovascular. Left ventricular dysfunction reduces cardiac output and alters the CO₂ feedback loop to the brainstem, creating instability in ventilatory control. Opioid medications suppress the μ-opioid receptors in the pre-Bötzinger complex, directly dampening the respiratory rhythm generator. High-altitude exposure causes hypocapnia, reducing the respiratory drive below the apnea threshold.

Complex sleep apnea's emergence on CPAP is associated with high loop gain (quantified as a ratio ≥1, meaning the respiratory system overreacts to perturbations), low arousal threshold, and pre-existing subclinical central events masked by obstructive pathology. Patients with heart failure or prior stroke face elevated risk.

The sleep and cardiovascular health relationship is bidirectional: OSA-induced intermittent hypoxia and sympathetic activation elevate blood pressure and accelerate atherosclerosis, while cardiac disease promotes CSA through the mechanisms above.

Classification Boundaries

Distinguishing the three subtypes requires attended polysomnography (PSG) or, in specific circumstances, home sleep testing validated for OSA. PSG measures airflow via thermistor and pressure transducer, chest and abdominal respiratory effort via inductance plethysmography, and oxyhemoglobin saturation via pulse oximetry — all simultaneously.

The key classification criterion:
- Obstructive apnea: cessation of airflow ≥10 seconds WITH continued respiratory effort.
- Central apnea: cessation of airflow ≥10 seconds WITHOUT respiratory effort.
- Mixed apnea: begins as central (no effort), then effort resumes before airflow restoration.
- Hypopnea: ≥30% reduction in airflow associated with ≥3% oxyhemoglobin desaturation or an arousal (per 2012 AASM recommended hypopnea scoring rule; a 4% desaturation-only rule constitutes the alternative scoring criteria used by Medicare's coverage policies).

Treatment-emergent CSA is diagnosed when the AHI on CPAP shows ≥5 central apneas or hypopneas per hour and the central index exceeds 50% of residual respiratory events, after elimination of obstructive events. A full description of how polysomnography generates these measurements is covered in the sleep study: polysomnography reference.

Tradeoffs and Tensions

Several unresolved tensions structure the clinical and scientific landscape around sleep apnea.

Hypopnea scoring rules and diagnosis rates: The 3% desaturation rule produces systematically higher AHI values than the 4% rule. A patient may qualify as having moderate OSA under one scoring convention and mild OSA under the other. The AASM recommends the 3% rule; the Centers for Medicare & Medicaid Services (CMS) historically used the 4% rule for CPAP coverage determinations, creating a misalignment between clinical and reimbursement thresholds.

CPAP adherence and outcome data: CPAP is the most thoroughly studied treatment for moderate-to-severe OSA, but randomized controlled trial data from the SAVE trial (published in The New England Journal of Medicine, 2016) found no significant reduction in the rate of serious cardiovascular events in patients with OSA and established cardiovascular disease assigned to CPAP versus usual care. This outcome challenges assumptions about the causal chain between CPAP use and cardiovascular risk reduction, even as observational studies and mechanistic research strongly implicate untreated OSA in cardiovascular harm.

Treatment-emergent CSA resolution rates: Between 60% and 80% of complex sleep apnea cases resolve spontaneously with continued CPAP use, according to data reviewed in the AASM's clinical practice guidance, making the clinical significance of the diagnosis contested. Clinicians debate whether adaptive servo-ventilation (ASV) should be deployed immediately or whether a trial of standard CPAP is warranted first — particularly given that the SERVE-HF trial found increased mortality with ASV in patients with CSA and reduced left ventricular ejection fraction below 45%.

Common Misconceptions

"Sleep apnea only affects overweight individuals."
While elevated BMI is a significant risk factor, lean individuals with craniofacial anatomy — particularly retrognathia or a narrow mandibular arch — develop OSA at normal weight. Epidemiological data from Asian-Pacific populations show OSA prevalence at lower BMI thresholds than in European-ancestry cohorts, explained largely by anatomical differences.

"Snoring confirms sleep apnea."
Snoring indicates partial airway narrowing but does not confirm apnea. Conversely, not all individuals with OSA snore audibly. Central sleep apnea commonly occurs without snoring because the obstruction is neurological, not mechanical.

"CPAP cures sleep apnea."
CPAP controls apneic events during use but does not alter the underlying anatomy or physiology. Cessation of CPAP therapy results in return of the original apnea severity. Surgical interventions such as uvulopalatopharyngoplasty (UPPP) or maxillomandibular advancement (MMA) address structural anatomy, but cure rates vary and relapse occurs.

"Home sleep tests diagnose all types of sleep apnea."
Home sleep testing (HST) devices validated by the AASM are FDA-cleared for OSA diagnosis in adults with high pretest probability and without significant comorbidities. HST is not validated for CSA or complex sleep apnea diagnosis, as these require simultaneous measurement of effort channels and may require EEG-based sleep staging to accurately calculate the AHI. The limitations of home-based evaluation are detailed in the home sleep testing reference.

Checklist or Steps

The following sequence reflects the standard diagnostic pathway described in AASM clinical practice guidelines — presented as a process map, not as clinical instructions.

  1. Symptom and risk factor documentation: Establish presence of witnessed apneas, excessive daytime sleepiness (Epworth Sleepiness Scale score ≥10), nocturnal gasping, nocturia frequency, and morning headache.
  2. Physical examination parameters: Record BMI, neck circumference (≥40 cm in women, ≥43 cm in men as referenced thresholds in AASM screening literature), Mallampati score, tonsil size, and jaw position relative to maxilla.
  3. Pretest probability stratification: Apply a validated screening tool (e.g., STOP-BANG questionnaire) to stratify low, intermediate, or high pretest probability for moderate-to-severe OSA.
  4. Diagnostic study selection: High-pretest-probability uncomplicated OSA → consider home sleep testing. Suspected CSA, complex apnea, significant cardiopulmonary comorbidity, or hypoventilation → in-laboratory polysomnography indicated per AASM guidelines.
  5. Diagnostic study interpretation: Calculate AHI, Respiratory Disturbance Index (RDI), oxygen desaturation index (ODI), time spent below 90% SpO₂, and arousal index. Classify subtype per ICSD-3 criteria.
  6. Treatment matching by subtype: OSA → PAP therapy, positional therapy, oral appliance, or surgical evaluation. CSA → treat underlying etiology; consider ASV (with ejection fraction contraindication check). Complex → continued CPAP with follow-up titration PSG at 8–12 weeks.
  7. Treatment efficacy verification: Residual AHI on PAP therapy reviewed via device download data or repeat PSG; AHI ≥5 on therapy warrants reassessment.
  8. Long-term surveillance: Annual reassessment of weight, symptoms, and device adherence data; rescoring of index if clinical status changes significantly.

The CPAP and positive airway pressure therapy page covers step 6 for PAP-based interventions in greater detail.

Reference Table or Matrix

Sleep Apnea Subtype Comparison

Feature Obstructive (OSA) Central (CSA) Complex (CompSAS)
Airflow cessation Yes (≥10 sec) Yes (≥10 sec) Yes
Respiratory effort during event Present Absent Absent initially, then present (mixed) or absent on CPAP
Primary mechanism Upper airway collapse Brainstem respiratory drive failure Ventilatory instability (high loop gain) unmasked by CPAP
Key risk factors Obesity, craniofacial anatomy, male sex Heart failure, stroke, opioids, high altitude Pre-existing subclinical central events, high loop gain, heart failure
EEG-based PSG required? Not always (HST acceptable in uncomplicated cases) Yes Yes
First-line treatment CPAP / APAP Treat underlying cause; ASV (select cases) Continued CPAP; ASV if central events persist
Snoring Common Uncommon Variable
Cheyne-Stokes pattern Absent Present in heart failure–related CSA May be present
AASM ICSD-3 classification Obstructive Sleep Apnea Central Sleep Apnea (multiple subtypes) Treatment-Emergent Central Sleep Apnea
Resolved by CPAP alone Yes (obstructive events) No In 60–80% of cases (AASM data)

For a full overview of sleep disorders alongside their diagnostic frameworks, the National Sleep Authority home reference provides a structured entry point across all major categories.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)